Posted by Michael Wonder on 13 May 2024
Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease (final guidance)
8 May 2024 - NICE has published final evidence-based recommendations on the use of remdesivir (Veklury) and tixagevimab and cilgavimab (Evusheld) for the treatment of patients with COVID-19 disease.
Remdesivir is recommended as an option for the treatment of certain adults and children with COVID‑19 disease in hospitals.
Tixagevimab and cilgavimab is not recommended for the treatment of adults with COVID‑19 disease who do not need supplemental oxygen and who have an increased risk of progression to severe COVID‑19 disease.
